This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Opinion: Discussing the potential of Chinook's Atrasentan, currently in development for the treatment of IgAN
Ticker(s): NVS, KDNYWho's the expert?
- Clinical associate professor of Medicine, Nephrology Division
- Treats 25 patients with IgAN
- Familiar with the data released from the phase 2b ORIGIN clinical trial and the phase 3 ALIGN study
Interview GoalThe focus of this interview will be on the results from the phase 3 ALIGN study regarding Chinook's Atrasentan for treatment of IgAN
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
